1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsMetabolic Dysregulation and Cancer Risk Program, Research Grants: a Transdisciplinary Approach to Obesity-Associated Research (U01 Clinical Trial Optional) is sponsored by National Cancer Institute (NCI). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Metabolic Dysregulation & Cancer Risk Program | EGRP/DCCPS/NCI/NIH Metabolic Dysregulation and Cancer Risk Program: A Transdisciplinary Approach to Obesity-Associated Cancer Research Have questions about this topic or need additional assistance?
Environmental Epidemiology Branch, Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences Cancer Immunology, Hematology, and Etiology Branch, Division of Cancer Biology Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention Integrated Networks Branch, Center to Reduce Cancer Health Disparities More than 13 different cancers are associated with obesity, although the precise mechanisms underpinning the obesity and cancer link are unclear.
In July 2021, NCI published two funding opportunity announcements, RFA-CA-21-021 and RFA-CA-21-022 , inviting applications for research projects and a coordinating center for the Metabolic Dysregulation and Cancer Risk Program.
The Program, with participation from the Division of Cancer Control and Population Sciences , Division of Cancer Biology , Division of Cancer Prevention , and the Center to Reduce Cancer Health Disparities , reflects the cross-cutting interests in obesity and cancer research within NCI and the activities of the Trans-NCI Obesity and Cancer Work Group .
The overall purpose of the trans-NCI Metabolic Dysregulation and Cancer Risk Program is to enhance knowledge of the dynamics and underlying mechanisms that link obesity, metabolic dysregulation, and increased cancer risk in individuals and identify mechanisms that will enhance cancer risk prediction, screening for high-risk individuals in clinical settings, and potential targets for preventive and therapeutic interventions.
The Metabolic Dysregulation and Cancer Risk Program consists of one coordinating center and multiple research project grants. The project titles below link to additional information in NIH RePORTER. Ceramides as Novel Drivers of Metabolic Dysfunction and Colorectal Cancer Institution: University of Utah Contact Principal Investigator (PI): Mary C.
Playdon, PhD, MPH NCI Program Director: Tram Kim Lam, PhD, MPH ; Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences Decoding Mechanisms Underlying Metabolic Dysregulation in Obesity and Digestive Cancer Risk Institution: Brigham and Women’s Hospital Contact PI: Deirdre K.
Tobias, ScD NCI Program Director: Tram Kim Lam, PhD, MPH ; Environmental Epidemiology Branch, Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences Determine the Molecular and Metabolic Mechanisms by which A-FABP Links Dysregulated Lipid Metabolism-Induced Obesity/Breast Cancer Risk Institution: University of Iowa NCI Program Director: Phil Daschner, MSc ; Cancer Immunology, Hematology, and Etiology Branch, Division of Cancer Biology Determining the Contribution of Microbial-Derived Metabolites to Protective Immunity in Obesity-Driven Cancer Risk Institution: University of Tennessee Health Science Center Contact PI: Liza Makowski-Hayes, PhD, MS Program Director: Phil Dashcher, MSc ; Cancer Immunology, Hematology, and Etiology Branch, Division of Cancer Biology A Transdisciplinary Approach to Investigate Metabolic Dysregulation in Obese Parent and Child Dyads and Risk of Colorectal Cancer Institution: University of South Carolina Contact PI: James R.
Hébert, ScD Program Director: Sharon Ross, PhD, MPH ; Nutritional Science Research Group, Division of Cancer Prevention Metabolic Dysregulation and Cancer Risk Program Coordinating Center Institution: George Washington University Program Director: Tram Kim Lam, PhD, MPH ; Environmental Epidemiology Branch, Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences Environmental Epidemiology Branch, Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences Cancer Immunology, Hematology, and Etiology Branch, Division of Cancer Biology Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention Integrated Networks Branch, Center to Reduce Cancer Health Disparities Last Updated: 19 Aug, 2024
According to the current listing, eligibility includes: Nonprofits, Universities, State/local governments, For-profit organizations. Confirm the full requirements in the official notice before applying.
Metabolic Dysregulation and Cancer Risk Program, Research Grants: a Transdisciplinary Approach to Obesity-Associated Research (U01 Clinical Trial Optional) is funded by National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
On May 21, 2026, the National Cancer Institute posted RFA-CA-27-006, RFA-CA-27-007, and RFA-CA-27-008 — the three competitive renewals for the NCI Community Oncology Research Program. Combined FY 2027 commitments reach $147.5 million across roughly 57 awards: $74.5 million for up to 7 Research Bases, $73 million for up to 50 Community and Academic Community Sites. Pre-application webinars run June 16-18 this week. Applications are due August 18, 2026 with six-year project periods. For community hospitals, oncology consortia, and NCI-designated cancer centers, this is the single largest cancer clinical-trials infrastructure decision NCI makes until 2033.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article